CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

BACKGROUND: Minimal residual disease is the main issue of advanced ovarian cancer treatment. According to the literature and previous results, we hypothesized that Mesenchymal Stromal Cells (MSC) could support this minimal residual disease by protecting ovarian cancer cells (OCC) from chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Pasquier, Jennifer, Gosset, Marie, Geyl, Caroline, Hoarau-Véchot, Jessica, Chevrot, Audrey, Pocard, Marc, Mirshahi, Massoud, Lis, Raphael, Rafii, Arash, Touboul, Cyril
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817856/
https://www.ncbi.nlm.nih.gov/pubmed/29455640
http://dx.doi.org/10.1186/s12943-018-0787-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817856/
https://www.ncbi.nlm.nih.gov/pubmed/29455640
http://dx.doi.org/10.1186/s12943-018-0787-z

Ejemplares similares